Eras Alexis, Castillo Danna, Suárez Margarita, Vispo Nelson Santiago, Albericio Fernando, Rodriguez Hortensia
School of Chemical Sciences and Engineering, Yachay Tech University, Urcuquí, Ecuador.
Laboratorio de Síntesis Orgánica, Facultad de Química, Universidad de la Habana, La Habana, Cuba.
Front Chem. 2022 May 26;10:889083. doi: 10.3389/fchem.2022.889083. eCollection 2022.
Cancer is one of the diseases with the highest mortality rate. Treatments to mitigate cancer are usually so intense and invasive that they weaken the patient to cure as dangerous as the own disease. From some time ago until today, to reduce resistance generated by the constant administration of the drug and improve its pharmacokinetics, scientists have been developing drug delivery system (DDS) technology. DDS platforms aim to maximize the drugs' effectiveness by directing them to reach the affected area by the disease and, therefore, reduce the potential side effects. Erythrocytes, antibodies, and nanoparticles have been used as carriers. Eleven antibody-drug conjugates (ADCs) involving covalent linkage has been commercialized as a promising cancer treatment in the last years. This review describes the general features and applications of DDS focused on the covalent conjugation system that binds the antibody carrier to the cytotoxic drug.
癌症是死亡率最高的疾病之一。减轻癌症的治疗通常非常强烈且具有侵入性，以至于它们使患者变得虚弱，治愈过程与疾病本身一样危险。从一段时间以前到现在，为了降低因持续给药产生的耐药性并改善其药代动力学，科学家们一直在开发药物递送系统（DDS）技术。DDS平台旨在通过引导药物到达疾病感染区域来最大化药物的有效性，从而减少潜在的副作用。红细胞、抗体和纳米颗粒已被用作载体。在过去几年中，十一种涉及共价连接的抗体药物偶联物（ADC）已作为一种有前景的癌症治疗方法商业化。本综述描述了DDS的一般特征和应用，重点是将抗体载体与细胞毒性药物结合的共价偶联系统。
